Adding Liraglutide to High Dose Insulin: Breaking the Cycle - Full Text View

Purpose

The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (>1.8 units/kg/day) in patients with uncontrolled (HbA1c >7.5%) type 2 diabetes mellitus will improve blood sugar control.

It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and assesses blood pressure, lipid profile, and liver function. Finally it will look at patient quality of life and safety.

Condition	Intervention	Phase
Type 2 Diabetes Mellitus Obesity	Drug: Liraglutide Drug: Saline	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment
Official Title:	Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Medicines

Drug Information available for: Insulin Liraglutide

Genetic and Rare Diseases Information Center resources: Visceral Steatosis

U.S. FDA Resources

Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:

Glycemic control measured by HbA1c [ Time Frame: 2-months and 6-months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Pancreatic and Hepatic triglyceride content [ Time Frame: 6-months ] [ Designated as safety issue: No ]
Magnetic Resonance Spectroscopy scan of liver and pancreas
Weight [ Time Frame: 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: No ]
Beta-Cell Function [ Time Frame: 6-months ] [ Designated as safety issue: No ]
Mixed Meal Challenge Test over 4 hours measuring glucose, c-peptide, and insulin. Then C-peptide area under the curve (AUC)and change in c-peptide over change in glucose will be calculated.
Glucagon [ Time Frame: 6-months ] [ Designated as safety issue: No ]
Measured during mixed meal challenge test.
Total Daily Insulin Dose [ Time Frame: 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: No ]
Calculated at each visit by summing all insulin shots of all types over a 24 hrs period. The average of the 3 most recent 24 hrs prior to each visit will be used.
Number of daily injections [ Time Frame: 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: No ]
Counted by adding all shots regardless of the type of insulin. The average of the 3 most recent 24 hrs prior to each visit will be used.
Blood Pressure [ Time Frame: 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: No ]
Lipid Profile [ Time Frame: 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: No ]
Liver Function blood test [ Time Frame: 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: No ]
Hypoglycemic Events [ Time Frame: 3-, 7-, 14-days and 1-, 2-, 4-, and 6-months ] [ Designated as safety issue: Yes ]
Reported by patient as any blood glucose <70 mg/dl or symptoms of hypoglycemia with blood glucose >70 mg/dl
Quality of Life Survey [ Time Frame: 6-months ] [ Designated as safety issue: No ]


Estimated Enrollment:	80
Study Start Date:	January 2012
Estimated Study Completion Date:	June 2015
Estimated Primary Completion Date:	June 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Liraglutide	Drug: Liraglutide Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months Other Name: Victoza
Placebo Comparator: Saline injection	Drug: Saline Placebo injection of 1.8mg saline once daily for 6-months

Detailed Description:

Type 2 diabetes is a progressive disease with incessant beta-cell dysfunction that often ultimately requires insulin treatment. Patients requiring high insulin dosages represent a particular treatment challenge and often have uncontrolled glycemia despite progressive dose increases and are especially prone to insulin related lipotoxicity and weight gain.

Glucagon-like peptide agonists (GLP-1) such as liraglutide have many actions that position them to break the vicious cycle in this population through the following mechanisms: (1) weight loss; (2) improved hepatic steatosis; (3) improved pancreatic steatosis; (4) decreased glucagon levels; (5) improved beta-cell function.

The purpose of the study is to demonstrate that liraglutide is both effective and safe when added to a high dose insulin treatment regimen. Liraglutide will improve glycemic control, weight, metabolic parameters, as well as patient satisfaction, with minimal adverse events. The study also proposes to study the mechanisms through which such improvements might occur, especially beta-cell function, glucagon levels, and hepatic and pancreatic fat content.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetes mellitus
Insulin dose of >1.8 units/kg/day (represents total daily insulin dose, regardless of formulation, regimen, number of daily shots)
HbA1c ≥ 7.5% and ≤ 11%
Age ≥ 18
Stable comorbidities on stable treatment regimens
Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment
Ability to provide informed consent before any trial-related activities

Exclusion Criteria:

Type 1 diabetes mellitus
Any contraindication to the MRI procedure (metallic implants, severe claustrophobia, pregnancy, unable to lie still on a hard table for the duration of the procedure, weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller than the largest body circumference)
History of any pancreatic disease as it might interfere with the pancreatic TG measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic surgery)
End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and possible interference with accurate measurement of HbA1c
Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)
Unstable or decompensated comorbidities
Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
Severe gastroparesis
Pregnancy, breast feeding, intention to become pregnant, or not using adequate contraceptive measures
Organ transplant recipient or waiting list candidate
Steroid use (current or potential use during the trial)
Known/suspected allergy to trial medication, excipients, or related products
Contraindications to study medications, worded specifically as stated in the product's prescribing information
Non-English speaking volunteers since no interpreters are available and the safety of the volunteers could be jeopardized if adequate and reliable communication is not possible.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01505673

Contacts


Contact: Anna Vanderheiden, MD	214-648-0305	Anna.Vanderheiden@UTSouthwestern.edu
Contact: Ildiko Lingvay, MD	214-648-2779	Ildiko.Lingvay@utsouthwestern.edu

Locations


United States, Texas
UT Southwestern	Recruiting
Dallas, Texas, United States, 75390
Sub-Investigator: Lindsay B Harrison, MD
Principal Investigator: Ildiko Lingvay, MD
Sub-Investigator: Anna Vanderheiden, MD

Sponsors and Collaborators

Ildiko Lingvay

Novo Nordisk A/S

Investigators


Principal Investigator:	Ildiko Lingvay, MD	UT Southwestern

More Information

No publications provided


Responsible Party:	Ildiko Lingvay, Assistant Professor, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:	NCT01505673 History of Changes
Other Study ID Numbers:	IIS-000235
Study First Received:	January 4, 2012
Last Updated:	November 14, 2014
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Texas Southwestern Medical Center:


Insulin Glucagon-like peptide Liraglutide	Beta-Cell pancreatic steatosis hepatic steatosis

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Liraglutide	Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Hypoglycemic Agents Incretins Pharmacologic Actions Physiological Effects of Drugs

ClinicalTrials.gov processed this record on March 01, 2015